The current coronavirus (COVID-19) outbreak has been declared by WHO as a Public Health Emergency of International Concern according to the International Health Regulation.
It is crucial to rapidly gain a better understanding of the newly identified virus, especially in relation to potential clinical and public health measures that can be put to immediate use to improve patients’ health and/or contain the spread of COVID-19.
Collaboration of private companies, academia, international organisations, public bodies etc. has the potential to accelerate the development of therapeutics and diagnostics to tackle this current and future outbreaks. The actions resulting from this call will contribute to the pan-European efforts responding to this Public Health Emergency.Scope:
Proposals submitted under this topic are expected to advance the knowledge specifically on COVID-19 and more widely on the coronavirus family with the aim of contributing to an efficient patient management and/or public health preparedness and response to current and future outbreaks of coronavirus infection.
Considering that this is a newly identified virus, the scope of this topic remains broad and must address at least one of the following objectives:
Please note that preventive vaccines are specifically excluded from the scope of the call.Expected Impact:
Proposals must be timely, with rapid activation, to enable early and valuable outcomes to be established and should contribute to one or more of the following impacts:
Maximisation of the IMI2 JU public-private partnership value by harnessing support from different stakeholders, including the mobilisation of resources through the inclusion of contributing partners (EFPIA companies or organisations associated to EFPIA, and Associated Partners to IMI2 JU) providing contributions (in kind and/or financial), to reflect the public-private character of IMI2 JU actions.